

Supplementary Table 1. Lymphoma Therapies Received Prior to Pembrolizumab +/- Pomalidomide

Patient	Prior Therapies (number of cycles)
1	EPOCH (4), EPOCH-R ² (2)
2	R-EPOCH (6), R-ICE (3), ASCT, XRT to bone lesions
3	EPOCH (6), XRT to nodal disease, gem/ox (6), gem/ox (4), ICE (3)
4	R-EPOCH (3)
5	R-CHOP (1), R-EPOCH (2), R-ICE (1)
6	EPOCH-R ² (6), TEDD (5)
7	EPOCH-R ² (5), ICE (1)
8	R-CHOP (6), R-ICE (3), Lenalidomide (2), R-ESHAP (2)
9	R-CHOP (1), R-EPOCH (5)
10	R-CHOP (8), ICE (1)

ASCT indicates autologous stem cell transplant; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; ESHAP, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin; EPOCH, dose-adjusted infusional etoposide, vincristine and doxorubicin with cyclophosphamide and prednisone; gem/ox, gemcitabine and oxaliplatin; ICE, ifosfamide, carboplatin, and etoposide; R, rituximab; R², rituximab and lenalidomide; TEDD, temozolomide, etoposide, liposomal doxorubicin, and dexamethasone; XRT, radiation.